● TIER 3 — Information onlyGRADE A- (one large CVOT)GLP-1 / incretins & amylin
Efpeglenatide (Korea, Hanmi) [NEW, replaces Korea placeholder]
Origin: South Korea. Citations verified: yes. 1 human study record(s) in the FitClinicMD studies database.
GOALS · Weight loss
FDA status
Not an FDA-approved product
Compounding (503A/503B)
Status varies — see notes
DEA
Not listed as controlled
WADA (sport)
Not specified
Human evidence · 1
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. NEJM 2021.
Reference only. This page summarizes publicly available regulatory and research information about Efpeglenatide (Korea, Hanmi) [NEW, replaces Korea placeholder]. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.